ProfileGDS5678 / 1431789_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 89% 88% 88% 87% 89% 83% 86% 88% 89% 89% 87% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2096484
GSM967853U87-EV human glioblastoma xenograft - Control 27.1341689
GSM967854U87-EV human glioblastoma xenograft - Control 36.8193188
GSM967855U87-EV human glioblastoma xenograft - Control 46.9548188
GSM967856U87-EV human glioblastoma xenograft - Control 56.8182487
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7300989
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9209883
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5319586
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8211988
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0628589
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9684989
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7566687
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8722388
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7927988